Titlebook: Evidence-Based Pharmacovigilance; Clinical and Quantit Andrew Bate Book 2018 Springer Science+Business Media, LLC, part of Springer Nature

退縮

書目名稱Evidence-Based Pharmacovigilance影響因子(影響力)




書目名稱Evidence-Based Pharmacovigilance影響因子(影響力)學(xué)科排名




書目名稱Evidence-Based Pharmacovigilance網(wǎng)絡(luò)公開度




書目名稱Evidence-Based Pharmacovigilance網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Evidence-Based Pharmacovigilance被引頻次




書目名稱Evidence-Based Pharmacovigilance被引頻次學(xué)科排名




書目名稱Evidence-Based Pharmacovigilance年度引用




書目名稱Evidence-Based Pharmacovigilance年度引用學(xué)科排名




書目名稱Evidence-Based Pharmacovigilance讀者反饋




書目名稱Evidence-Based Pharmacovigilance讀者反饋學(xué)科排名

止痛藥

placebo-effect

要素

Pediatric Pharmacovigilance: Current Practice and Future Perspectives,ype, suspected medicines, age and gender of the child, and type of reporter. Secondly to review experiences with the EU pediatric regulation and its impact on the conduction of pediatric clinical trials in Europe. This literature review showed that occurrence of ADRs in pediatric populations differs

Insensate

Detecting Safety Issues in Clinical Trials, is collected and often undergoes a detailed review by the sponsor. Detecting safety issues during a trial has revolved primarily around the Data Safety Monitoring Board (DSMB) who review unblinded summarized data and case reports. Final trial publications typically contain descriptive analyses on t

Flatus

Developments and Future Directions of Prescription-Based Observational Cohort Pharmacovigilance,development as compared to during use within routine clinical practice, post marketing. Changes in pharmacovigilance regulations and legislation have given greater weight to the importance of post-marketing observational research and understanding more regarding natural variation in patients and the

Flatus

Electronic Health Record, Transactional Insurance Claims, and Distributed Databases in Pharmacovigith record databases, traditional insurance claims databases, and distributed data networks. Strengths, weaknesses, considerations, and examples are presented. Finally, the chapter covers the concepts and challenges of data linkage across resources and offers several future perspectives on data avail

緩解

evasive

Patient Reported Outcomes in Pharmacovigilance,first hand from those who have experienced the adverse drug reactions. These experiences are richer in context and information of the impact of an ADR as compared to information from healthcare professionals. New technologies (i.e., Internet) have made the collection of patient reported information

巨碩

Evidence-Based Pharmacovigilance for Medicines Used in Public Health Programs in Africa,me for International Drug Monitoring having increased from just 5 in the year 2000 to 35 in 2017. However, published information indicates that Africa’s contribution of individual case safety reports (ICSRs) to the WHO ICSR database (VigiBase) is paltry currently standing at less than 1% of the >14